An immunoradiometric assay (IRP) involving a monoclonal antibody (MAb OC1 25) to an ovarian carcinoma-associated antigenic determinant (CA 125) has been tested as one component in a strategy for early detection of epithelial ovarian cancer. We characterized one confirmed "falsepositive" sample by murine antibody blocking studies, Western blotting, immunoaffinity, size-exclusion chromatography, and reactivity with polyclonal rabbit antisera to CA 125 antigen. The positiveresponse of this serum in the CA 125 IRMA was due to a human 1gM. The discrepant 1gM was As currently constructed, however, the diagnostic utility of the CA 125 mza for screening apparently healthy women for ovarian cancer may be limited by the occurrence of "false positives." For example, in a study including 988 nonpregnant patients screened at a gynecological clinic, Nioffet al. (6) reported that CA 125 concentrations were abnormally high (>65 kilo-arb.units/L) in 1.1% of patients, a prevalence that dropped to about 0.5% upon analysis of a second serum sample. Because most women in this group were pre- remain (2,6,8) . Thus, a low frequency of false-positive samples would remain in the screened populations. Reducing the incidence of these false-positive results would undoubtedly enhance the diagnostic usefulness of the CA 125 mzi.&.
antigen. The positiveresponse of this serum in the CA 125 IRMA was due to a human 1gM. The discrepant 1gM was isolated from the serum by successive immunoaffinity steps with nonspecific munne MAb, MAb OC1 25, and goat antibodies to human 1gM Fc. Purified 1gM inhibited the binding of MAb OC1 25 to CA 125. Furthermore, rabbit antisera to CA 125 antigen competitively inhibited the binding of MAb OC1 25 to both CA 125 and the discrepant 1gM. The discrepant activity thus appears to reflect binding of this human 1gM to a idiotope of MAb OC1 25. Radioiodination of MAb OC1 25 by a different technique eliminated the discrepant activity and decreased the incidence of CA 125 positivity in an at-risk population of apparently healthy women, increasing the specificity of the IRMA to 99.8% in this group.
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The immunoradiometric assay (nth!a) of CA 125, based on the use of monoclonal antibody (MAb) 0C125 (1, 2), has demonstrated excellent sensitivity and predictive value as a serum marker assay, both for identifying patients with residual ovarian cancer after primary therapy (3), and for monitoring the clinical course of ovarian carcinomas (4)#{149}3 The excellent specificity of the CA 125 mr has led Einhorn et al. (5) to suggest the use of this test as a diagnostic adjunct for discriminating benign from malignant pelvic masses.
As currently constructed, however, the diagnostic utility of the CA 125 mza for screening apparently healthy women for ovarian cancer may be limited by the occurrence of "false positives." For example, in a study including 988 nonpregnant patients screened at a gynecological clinic, Nioffet al. (6) reported that CA 125 concentrations were abnormally high (>65 kilo-arb.units/L) in 1.1% of patients, a prevalence that dropped to about 0.5% upon analysis of a second serum sample. Because most women in this group were pre- 
Materials and Methods

CA 125 Analysis and Immunoaffinity Techniques
All the immunoaffinity and antigen analysis techniques used here-including gel chromatography, Western blotting, and MAb 0C125 affinity chromatography-have been described in detail elsewhere (9). Affinity chromatography for purifying the material in serum from BK. that showed activity in the CA 125 m was modified from that described (9) by using phosphate-buffered saline (PBS; P043 30 mmol/L, NaC1 150 mmol/L), pH 7.4, and MAb 0C125 or anti-tetanus toxoid MAb coupled to Affi-gel 10 (Bio-Rad Laboratories, Richmond, CA), 3 and infectious mononucleosis were also from the Centocor serum bank.
Results
Confirmationof the False-PositiveNature of B.K.'s Serum Sample
Upon reveipt of the discrepant sample from B.K., we sought to establish whether it indeed contained increased CA 125 concentrations or was a false-positive specimen.
Initial tests demonstrated that the agent responsible for apparently increased CA 125 IRMA values did not resemble the CA 125 antigen in its biochemical behavior (a) its molecular mass (870 kDa) as assessed by HPLC chromatography is less than that reported for serum CA 125 antigen (9) ( Figure 1); (b) Figure 2) .
Specificity of B.K. Anti-MurineImmunoglobulinResponse
We performed CA 125 assays on B.K. discrepant serum in the presence of increasing concentrations of both monoclenal and polyclonal BALB/c-derived murine immunoglobulins. Similar experiments were performed with heat-aggregated murine inamunoglobulins. 
Concentrations of
12 8 concentrations exceeding 18 kilo-arb.units/L (data not shown).
Isolationof the BK. Discrepant Material
Because the activity of B.K.'s sera in the CA 125 IRMA could be neutralized with MAb 0C125, we attempted to bind it to MAb 0C125 coupled to a solid matrix. The material bound to the MAb OC125 Affi-Gel 10 affinity column very rapidly, and could be eluted with 50 mmol/L diethylamine, with 85% recovery of activity. Less than 10% of the apparent CA 125 activity was in the column flowthrough. The molecular mass (870 kDa, Figure 1 ) of the discrepant material as determined by HPLC suggested that it was an 1gM. Therefore, we prepared and used an antihuman 1gM affinity column. More than 85% of the B.K. discrepant 1gM was bound to this column, and it could be eluted with 50 mmol/L diethylamine, with 80% recovery of activity (data not shown). These experiments were not consistent with the hypothesis that we were observing CA 125 antigen in immune complexes, because these would have been much larger and more heterogeneous than observed for B.K. discrepant activity (Figure 1 ). The Samples from women over 40 years of age with apparently IncreasedCA 125 (CA 125 >65 kIlo-arb.unttslL).These 11 samples represented 1% of the screened population (n = 1082). bDgp made from medical histories and pelvic examinationsattimeof sampling. Menstrual status not recorded.
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at least one previousor subsequent increase(three-to six-month sampling Intervals). 
Effect of Radiolodinatlon Method on Discrepant Activity
During a recent study of the effect of different radioiodination techniques upon the performance characteristics of the CA 125 ia, we noted that the method of radiolabeling MAb 0C125 had profound effects upon the apparent CA 125 IgG or F(ab')2 radiola- baled by the Bolton-Hunter method measured only 30 kiloarb.units/L when tracers labeled with lodogen were used ( Table 1 ). The B.K. sample did not give discrepant results when other Bolton-Hunter-labeled IgGis were substituted as tracer in the CA 125 IRMA (data not shown).
To investigate the generality of this phenomenon, we tested sera from 11 women with apparently increased CA 125, selected from a prescreened group of 1082 normal females over 40 years of age, using the Iodogen-radiolabeled OC125 tracer. Serum from at least three of the six women in this group demonstrated the same behavior as that from subject B.K.; i.e., they were positive in the CA 125 ni in which Bolton-Hunter-labeled 0C125 IgG and F(ab')2 tracer were used, but negative with lodogen tracer (Table 1 ). There are also some significant differences in CA 125 concentrations between the Bolton-Hunter-labeled IgG and F(ab')2 tracers. To determine the effect of radioiodination technique upon CA 125 concentrations in true positives, we did similar studies with serum samples from 20 patients with ovarian cancer. Bolton-Hunterand lodogen-labeled tracers gave very similar results in the CA 125 nu ( Table 2) .
Discussion
There are at least three hypotheses, not necessarily mutually exclusive, that could explain the B.K. cluded in the CA 125 nu and most other monoclonal antibody assays, and have been shown (2, 17) usually to block the activity of anti-murine immunoglobulin and polyclonal RF in human serum. In previous studies, however, no naturally occurring human antibody entirely specific for the Fab or F(ab')2 portion of a murine monoclonal antibody was found in normal individuals. Anti-Id antibodies to tumorassociated antigen murine MAbs have been reported, but only in patients who were actively immunized by injection of the antibody (15) .
We have found that in at least one case the discrepant or false-positive activity in the CA 125 m was ascribable to the presence of a highly specific component of human serum that simultaneously bound to murine MAb 0C125 on the solid phase and to radioiodinated MAb 0C125 tracer. Many facts support the hypothesis that this component is a human 1gM that binds to a MAb 0C125 idiotope: (a) it is biochemically unlike CA 125 antigen; (b) its relative molecular mass and reactivity with specific polyclonal antibodies imply that it is a human 1gM; (c) it inhibits the binding of MAb 0C125 to CA 125 antigen; (d) its binding to MAb 0C125 is inhibited by polyclonal rabbit antisera to CA 125 antigen; and (e) it reacts only with 0C125 IgG and F(ab')2, but this reactivity is decreased after a specific chemical modification of MAb 0C125.
Jerne ( Radioiodination of MAb 0C125 with lodogen instead of Bolton-Hunter reagent in some way altered part of the structure of MAb 0C125 and decreased the affinity of interaction with the B.K.-type human 1gM. The only apparent difference between the radiolabeling methods we used in the present study is that the Bolton-Hunter reagent reacts with lysine residues whereas lodogen oxidatively couples iodine to tyrosine residues. Dickerman et al. (20) This studywas supported in part by NIH grant R433 CA 40945-01 from the U.S.P.H.S. We thank Dr. Paul Kaplan for his suggestions, and Ms. Darnella Resetar for s#{233}ci-etarial help.
